ESPAD Survey: Vaping Prevalent among European Students

Sep.01.2022
ESPAD Survey: Vaping Prevalent among European Students
The ESPAD project investigates alcohol, tobacco, and drug use among 15-16 year old students in 35 European countries.

The European School Survey Project on Alcohol and Other Drugs (ESPAD) is the largest survey of alcohol, tobacco, and illegal drug use among 15-16 year old students in 35 European countries. It is coordinated by the Institute of Clinical Physiology of the National Research Council of Italy (CNR-Ifc). Using standardized methods since 1999, this survey is able to assess changes in young people's habits and has recently garnered interest from the World Health Organization.


Data shows that traditional tobacco cigarette use is declining among adolescents, possibly due to prevention and comparison policies implemented in many countries. However, concerning data about electronic cigarette use has emerged as a worrying trend. In response, the epidemiology and health services research department of CNR-Ifc conducted a study titled "Electronic Cigarette Use and Conventional Smoking Among European Students: Results From the 2019 ESPAD Survey," published in the journal Addiction, to analyze how tobacco control policies impact these habits.


In 2019, a study of approximately 100,000 ESPAD students found that 40.6% had tried traditional cigarettes at least once, with 19.3% currently being smokers. The percentage of smokers varied from 5.1% in Iceland to 32.4% in Italy. On the other hand, 37.8% of students reported trying e-cigarettes, with 12.4% currently using them (13.4% in Italy). According to the study's author, Sonia Cerrai, it can be assumed that young people's attitudes towards new smoking habits will continue to grow, due to the ease of access and perception of low risk.


In the ten countries analyzed, the use of electronic cigarettes has surpassed traditional smoking," stated Cerrai. "While electronic cigarettes may not necessarily contain nicotine, these tech products that are highly attractive to young people and very young individuals are frequently used in conjunction with traditional cigarettes, with usage ranging from 2% in Cyprus to 15% in Monaco (8.9% in Italy) within the sample.


However, implementing tobacco control policies by the government can also contribute to preventing smoking. "In this analysis, we used the Tobacco Control Scale index, which scores policies based on the measures taken," explained Cerrai. "We also considered some specific factors in our analysis: price increases showed a clear association with decreased use of two smoking methods. More spending on information campaigns and cessation programs only correlated with traditional smoking, while measures to prohibit the promotion and advertising of electronic devices were stricter.


According to researchers, the marketing for new devices emphasizes safety by reducing the risks associated with tobacco smoke exposure. However, this complete change in consumption patterns could lead to distractions for young people, who are also familiar with prevention initiatives and programs implemented in the past 20 years.


Statement: 1. The content of this article is compiled from third-party information, provided solely for industry exchange and learning purposes. 2. This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the authenticity and accuracy of the article's content. The compilation of this article is only for industry exchange and research purposes. 3. Due to limitations in the compilation process, the compiled article may not fully match the original text. Please refer to the original text for accuracy. 4. 2FIRSTS fully aligns with the Chinese government on any statements and positions related to domestic, Hong Kong, Macau, Taiwan, and foreign issues. 5. Copyright for compiled information belongs to the original media and author. Please contact us for removal if there is any infringement.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Malaysia Liquid Nicotine Returns to Poisons List, Leaving Vape Retail and RM354 Million Tax Collection in Legal Uncertainty
Malaysia Liquid Nicotine Returns to Poisons List, Leaving Vape Retail and RM354 Million Tax Collection in Legal Uncertainty
Malaysia’s withdrawal of its appeal in a landmark liquid-nicotine case has left a High Court ruling that struck down the 2023 nicotine exemption in force, bringing liquid and gel nicotine used in vaping products back under the Poisons Act 1952. At the same time, the Control of Smoking Products for Public Health Act 2024 continues to provide a regulatory framework for vaping products, creating uncertainty over retail sales, taxation and existing inventory. MPs are calling for nicotine vape sales and excise collection to stop, including refunds of more than RM354 million collected since 2023, while industry and consumer groups are asking the government to clarify the current legal position.
Sep.04
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
NAS 2026 | Cliff Douglas: Risk Continuum Should Play a Central Role in Tobacco Policy
NAS 2026 | Cliff Douglas: Risk Continuum Should Play a Central Role in Tobacco Policy
Cliff Douglas, a veteran U.S. tobacco-control and public health policy figure, told NAS 2026 that the “continuum of risk” should play a central role in tobacco policy. He called for clearer market pathways, stronger risk communication, differentiated regulation and enforcement, and said possible FDA reforms to PMTA reviews could be a “welcome correction” if they create a more efficient, predictable route for scientifically substantiated lower-risk products. Read 2Firsts’ on-site coverage.
Sep.26
Product | JTI Launches Ploom AURA Teal Electric Pop in South Korea, Its First Dual-Color Edition
Product | JTI Launches Ploom AURA Teal Electric Pop in South Korea, Its First Dual-Color Edition
JTI Korea launched the Ploom AURA Teal Electric Pop limited edition in South Korea on September 1, 2026, marking the first dual-color design in the Ploom AURA range. The device combines a dark green body with teal accents and is accompanied by matching Front Panel, Back Cover and Pocket Bag accessories. The standalone device is priced at KRW 29,000, with three additional device-and-accessory bundles available. The release continues JTI Korea's use of limited colorways and interchangeable accessories to expand the Ploom AURA portfolio without introducing a new hardware platform.
Sep.03
Special Report | Altria Subsidiaries Sue FDA to Vacate 2021 PMTA Rule as Agency Moves to Speed Reviews
Special Report | Altria Subsidiaries Sue FDA to Vacate 2021 PMTA Rule as Agency Moves to Speed Reviews
2Firsts reviewed the original federal court complaint filed by Altria subsidiaries Helix Innovations and NJOY on Sept. 2 challenging FDA’s 2021 PMTA rule. The lawsuit questions whether FDA’s review process complies with the Tobacco Control Act’s 180-day timeline, even as the agency moves to accelerate PMTA reviews and issues more marketing orders. Drawing on the complaint, FDA records, government audits and recent court rulings, 2Firsts examines the legal arguments, supporting evidence and potential implications for the U.S. tobacco review system.
Regulations
Sep.03
New York’s 75% Wholesale Tax on Nicotine Pouches Takes Effect Sept. 1, With Aug. 31 Inventory Subject to Floor Tax
New York’s 75% Wholesale Tax on Nicotine Pouches Takes Effect Sept. 1, With Aug. 31 Inventory Subject to Floor Tax
New York State will extend its tobacco products tax to “alternative nicotine products,” including tobacco-free nicotine pouches, from September 1, 2026, at a rate of 75% of the wholesale price. Distributors, wholesalers and retailers must also inventory products held as of 11:59 p.m. on August 31 and pay a floor tax. Vapor products are excluded from the new category and remain subject to New York's separate 20% supplemental sales tax on the retail price.
Aug.26